Stocks to Watch: SVRN, Inovio, Intel

By Katherine Hamilton


SVRN received a letter from Nasdaq stating that it no longer meets the terms necessary to be listed on the market. The stock slid 8% to $27.01 after the bell Friday.

Inovio Pharmaceuticals got accelerated approval from the Food and Drug Administration for its drug Voceryq. Shares nearly quadrupled to $2.21 in after-hours trading.

Intel shed another $1.5% to $64.77 after the bell, following a 29% drop in day trading, as investors were displeased with its latest earnings report.


Write to Katherine Hamilton at katherine.hamilton@wsj.com


(END) Dow Jones Newswires

October 30, 2026 18:35 ET (22:35 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center